R&D Projects

Strengthening competitive positioning in drug development

LaunXP is pursuing a three-track innovation development strategy focused on cancer drug research and development. This includes developing 505(b)(1) new chemical entity (NCE) drugs, exploring new uses for existing medications (505(b)(2)), and developing virus-like particle and nanoparticle formulations for precision drug delivery in cancer treatment.

505(b)(1)

Develop 505(b)(1) new chemical entity (NCE) drugs.

505(b)(1) new chemical entity (New Chemical Entity, NCE) drugs are innovative and can offer entirely new treatment options to address unmet medical needs.

Preclinical

IND

Phase 1

Phase 2

Phase 3

Market

Solid Tumor

Stage: Phase 1

FLT3-mutated Acute Myeloid Leukemia

Stage: Preclinical

Non-small cell lung cancer, Alzheimer's disease

Stage: Preclinical

505(b)(2)

Explore new indications for 505(b)(2) designation​

The 505(b)(2) new drug development process involves modifying an existing drug’s formulation, delivery route, dosage, or approved use. This approach allows referencing existing clinical data or published literature when applying for a new drug, which can accelerate time to market, reduce development costs, and provide more treatment options to patients earlier.

Preclinical

IND

Phase 1

Phase 2

Phase 3

Market

Triple Negative Breast Cancer

Stage: Phase 2 (PoC)

Pancreatic Cancer

Stage: Preclinical

Virus-like particles

Research is underway on virus-like particles and nano-formulation anticancer drug

We are expecting an increase in the therapeutic effect of pharmaceuticals through precise drug delivery. We are looking forward to providing more efficient therapies and improving the quality of life.

505(b)(2)

Explore new indications for 505(b)(2) designation​

The 505(b)(2) new drug development process involves modifying an existing drug’s formulation, delivery route, dosage, or approved use. This approach allows referencing existing clinical data or published literature when applying for a new drug, which can accelerate time to market, reduce development costs, and provide more treatment options to patients earlier.

Indications

Preclinical

Preclinical

Preclinical

Preclinical

Preclinical

Preclinical

Triple Negative Breast Cancer

Proof of Concept

Triple Negative Breat Cancer

Proof of Concept